Valeant’s (VRX) Fall from Investing Grace

In my last post, I looked at how the pharmaceutical and biotechnology businesses have diverged, especially in the last decade, and the implications for earnings, R&D and market pricing of these companies. The pharmaceutical business, in particular, faces a new landscape with many companies still stuck with a business model that does not work in […] View the full post at: Valeant’s (VRX) Fall from Investing Grace Related posts: Savings Grace – by the Charts Cram and Jam Will the Homeownership Rate Fall to 63.5 Percent by 2020?